Nicolas Leupin

1.7k total citations
29 papers, 730 citations indexed

About

Nicolas Leupin is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Nicolas Leupin has authored 29 papers receiving a total of 730 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Hematology and 9 papers in Oncology. Recurrent topics in Nicolas Leupin's work include Chronic Lymphocytic Leukemia Research (7 papers), Protein Degradation and Inhibitors (6 papers) and Acute Myeloid Leukemia Research (5 papers). Nicolas Leupin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Protein Degradation and Inhibitors (6 papers) and Acute Myeloid Leukemia Research (5 papers). Nicolas Leupin collaborates with scholars based in Switzerland, United States and Belgium. Nicolas Leupin's co-authors include Hans de Haard, Torsten Dreier, Peter Ulrichts, E. Sally Ward, Erik Hofman, F. Javier Enriquez, Valérie Hanssens, Antonio Guglietta, Raimund J. Ober and Peter Verheesen and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nicolas Leupin

28 papers receiving 711 citations

Peers

Nicolas Leupin
Rachel Koldej Australia
R. Handgretinger Germany
Jun Takizawa Japan
Keitaro Tsushita Japan
Sietse Q. Nagelkerke Netherlands
WM Roberts United States
R Angonin France
Kentaro Fujii Japan
T Philip France
Lisa Durkin United States
Rachel Koldej Australia
Nicolas Leupin
Citations per year, relative to Nicolas Leupin Nicolas Leupin (= 1×) peers Rachel Koldej

Countries citing papers authored by Nicolas Leupin

Since Specialization
Citations

This map shows the geographic impact of Nicolas Leupin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Leupin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Leupin more than expected).

Fields of papers citing papers by Nicolas Leupin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Leupin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Leupin. The network helps show where Nicolas Leupin may publish in the future.

Co-authorship network of co-authors of Nicolas Leupin

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Leupin. A scholar is included among the top collaborators of Nicolas Leupin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Leupin. Nicolas Leupin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Newland, Adrian C., Blanca Sánchez‐González, László Rejtő, et al.. (2019). Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia. Blood. 134(Supplement_1). 895–895. 9 indexed citations
4.
Ulrichts, Peter, Antonio Guglietta, Torsten Dreier, et al.. (2018). Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. Journal of Clinical Investigation. 128(10). 4372–4386. 251 indexed citations
5.
Ochsenbein, Adrian F., Carsten Riether, Ulrike Bacher, et al.. (2018). Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial. Blood. 132(Supplement 1). 2680–2680. 16 indexed citations
6.
Aftimos, Philippe, Christian Rolfo, Sylvie Rottey, et al.. (2017). Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clinical Cancer Research. 23(21). 6411–6420. 47 indexed citations
7.
Hinterbrandner, Magdalena, Thomas Pabst, Luc Van Rompaey, et al.. (2017). Blocking CD70/CD27 Signaling in Combination with Hypomethylating Agents Eradicates Human CD34+ AML Stem and Progenitor Cells in Vitro and In Vivo. Blood. 130. 2652–2652. 5 indexed citations
8.
Ulrichts, Peter, et al.. (2016). Argx-113, a Novel Fc-Based Approach for Antibody-Induced Pathologies Such As Primary Immune Thrombocytopenia. Blood. 128(22). 4919–4919. 4 indexed citations
9.
Bahlis, Nizar J., Alessandro Corso, Lars‐Olof Mügge, et al.. (2015). Impact of Response in Patients (Pts) With Stem Cell Transplant (SCT)-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Treated With Continuous Lenalidomide + Low-Dose Dexamethasone (Rd) in the FIRST Trial. Clinical Lymphoma Myeloma & Leukemia. 15. e56–e56. 2 indexed citations
10.
Leupin, Nicolas, Jan C. Schuller, Max Solenthaler, et al.. (2010). Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leukemia & lymphoma. 51(4). 613–619. 6 indexed citations
11.
Schuller, Jan C., Michael Mayer, Doris Lanz, et al.. (2009). A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials. Contemporary Clinical Trials. 30(3). 201–204. 2 indexed citations
12.
Leupin, Nicolas, et al.. (2009). Holiday souvenirs from the Mediterranean: Three instructive cases of visceral leishmaniasis. Scandinavian Journal of Infectious Diseases. 41(10). 777–781. 6 indexed citations
13.
Leupin, Nicolas, et al.. (2008). Lymphom der Prostata – Diagnose auf den „zweiten Stich“. Medizinische Klinik. 103(4). 245–248.
14.
Rizzi, Mattia, Mario P. Tschan, Christian Britschgi, et al.. (2007). The death-associated protein kinase 2 is up-regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells. Journal of Leukocyte Biology. 81(6). 1599–1608. 43 indexed citations
15.
Leupin, Nicolas, Jan C. Schuller, Max Solenthaler, et al.. (2007). The Combination of 2-CDA and Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL): A Prospective Multicenter Phase II Trial (SAKK 34/02).. Blood. 110(11). 2057–2057. 1 indexed citations
16.
Leupin, Nicolas, Alexandre Kuhn, Barbara Hügli, et al.. (2006). Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines. British Journal of Haematology. 135(4). 520–523. 9 indexed citations
17.
Leupin, Nicolas, Alexander U. Lüthi, Urban Novak, et al.. (2004). p73 Status in B-cell Chronic Lymphocytic Leukaemia. Leukemia & lymphoma. 45(6). 1205–1207. 22 indexed citations
18.
Leupin, Nicolas, Bruno Cenni, Urban Novak, et al.. (2003). Disparate expression of the PTEN gene: a novel finding in B‐cell chronic lymphocytic leukaemia (B‐CLL). British Journal of Haematology. 121(1). 97–100. 37 indexed citations
19.
Leupin, Nicolas, et al.. (2002). Acute Radiation Colitis in Patients Treated With Short-Term Preoperative Radiotherapy for Rectal Cancer. The American Journal of Surgical Pathology. 26(4). 498–504. 27 indexed citations
20.
Geiser, Marianne, et al.. (2000). Interaction of fungal spores with the lungs: Distribution and retention of inhaled puffball (Calvatia excipuliformis) spores. Journal of Allergy and Clinical Immunology. 106(1). 92–100. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachel Koldej Breakdown of academic impact, for papers by R. Handgretinger Breakdown of academic impact, for papers by Jun Takizawa Breakdown of academic impact, for papers by Keitaro Tsushita Breakdown of academic impact, for papers by Sietse Q. Nagelkerke Breakdown of academic impact, for papers by WM Roberts Breakdown of academic impact, for papers by R Angonin Breakdown of academic impact, for papers by Kentaro Fujii Breakdown of academic impact, for papers by T Philip Breakdown of academic impact, for papers by Lisa Durkin
Rankless by CCL
2026